Ani Pharmaceuticals (ANIP) Retained Earnings (2010 - 2026)

Ani Pharmaceuticals has disclosed Retained Earnings across 17 years of filings, most recently posting $620.2 million for Q2 2026.

• In Q2 2026, Retained Earnings rose 14.46% year-over-year to $620.2 million; the TTM figure through Jun 2026 stood at $620.2 million (up 14.46% YoY), while the FY2025 annual figure was $596.0 million, up 14.7% from the prior year.
• Retained Earnings came in at $620.2 million for Q2 2026 at Ani Pharmaceuticals, up from $608.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $620.2 million in Q2 2026 to a low of $391.1 million in Q1 2022.
• Average Retained Earnings over 5 years is $504.7 million, with a median of $516.9 million recorded in 2023.
• Year-over-year, Retained Earnings surged 80.87% in 2022 and gained 0.87% in 2024.
• Over 5 years, Retained Earnings stood at $403.9 million in 2022, then gained by 27.28% to $514.1 million in 2023, then climbed by 1.08% to $519.7 million in 2024, then increased by 14.7% to $596.0 million in 2025, then gained by 4.06% to $620.2 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $620.2 million in Q2 2026, $608.4 million in Q1 2026, and $596.0 million in Q4 2025.